BAUSCH HEALTH COMPANIES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.71 USD | +1.04% |
|
+0.23% | +8.60% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 10,545 | 7,385 | 9,921 | 2,273 | 2,929 | 3,194 | - | - |
| Enterprise Value (EV) 1 | 33,196 | 29,494 | 30,456 | 2,273 | 2,929 | 23,099 | 21,523 | 3,194 |
| P/E ratio | -5.89 x | -13.2 x | -10.5 x | -10.1 x | -4.95 x | 13.2 x | 8.46 x | 7.38 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 1.23 x | 0.92 x | 1.18 x | 0.28 x | 0.33 x | 0.34 x | 0.34 x | 0.32 x |
| EV / Revenue | 3.86 x | 3.67 x | 3.61 x | 0.28 x | 0.33 x | 2.46 x | 2.28 x | 0.32 x |
| EV / EBITDA | 9.3 x | 8.95 x | 8.77 x | 0.75 x | 0.97 x | 7.1 x | 6.56 x | 0.9 x |
| EV / FCF | 27 x | 36.5 x | 26.3 x | -2.4 x | 3.58 x | 15.2 x | 13.7 x | - |
| FCF Yield | 3.71% | 2.74% | 3.8% | -41.6% | 27.9% | 6.58% | 7.32% | - |
| Price to Book | 9.92 x | 13.8 x | - | - | - | -4.92 x | -21.8 x | - |
| Nbr of stocks (in thousands) | 352,431 | 355,053 | 359,331 | 361,868 | 365,195 | 366,673 | - | - |
| Reference price 2 | 29.92 | 20.80 | 27.61 | 6.280 | 8.020 | 8.710 | 8.710 | 8.710 |
| Announcement Date | 2/19/20 | 2/24/21 | 2/23/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8,601 | 8,027 | 8,434 | 8,124 | 8,757 | 9,386 | 9,453 | 9,909 |
| EBITDA 1 | 3,571 | 3,294 | 3,472 | 3,022 | 3,014 | 3,252 | 3,281 | 3,547 |
| EBIT 1 | 3,226 | 2,959 | 2,951 | 2,775 | 2,808 | 3,045 | 3,054 | 3,267 |
| Operating Margin | 37.51% | 36.86% | 34.99% | 34.16% | 32.07% | 32.44% | 32.31% | 32.97% |
| Earnings before Tax (EBT) 1 | -1,837 | -934 | -1,024 | -129 | -390 | 313.8 | 438.4 | 522.1 |
| Net income 1 | -1,788 | -560 | -948 | -225 | -592 | 336.2 | 381.2 | 431.7 |
| Net margin | -20.79% | -6.98% | -11.24% | -2.77% | -6.76% | 3.58% | 4.03% | 4.36% |
| EPS 2 | -5.080 | -1.580 | -2.640 | -0.6200 | -1.620 | 0.6575 | 1.030 | 1.180 |
| Free Cash Flow 1 | 1,231 | 809 | 1,157 | -946 | 817 | 1,521 | 1,576 | - |
| FCF margin | 14.31% | 10.08% | 13.72% | -11.64% | 9.33% | 16.2% | 16.67% | - |
| FCF Conversion (EBITDA) | 34.47% | 24.56% | 33.32% | - | 27.11% | 46.76% | 48.02% | - |
| FCF Conversion (Net income) | - | - | - | - | - | 452.33% | 413.29% | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/19/20 | 2/24/21 | 2/23/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,111 | 2,196 | 1,918 | 1,967 | 2,046 | 2,193 | 1,944 | 2,167 | 2,238 | 2,408 | 2,149 | 2,339 | 2,406 | 2,485 | 2,235 |
| EBITDA 1 | 885 | 909 | 732 | 701 | 766 | 823 | 588 | 727 | 830 | 869 | 714 | 793 | 840.2 | 869.6 | 791.9 |
| EBIT 1 | 755 | 773 | 618 | 587 | 668 | 771 | 494 | 651 | 747 | 812 | 707.7 | 753.5 | 784 | 791.9 | - |
| Operating Margin | 35.77% | 35.2% | 32.22% | 29.84% | 32.65% | 35.16% | 25.41% | 30.04% | 33.38% | 33.72% | 32.93% | 32.22% | 32.58% | 31.87% | - |
| Earnings before Tax (EBT) 1 | 216 | 21 | -82 | -129 | 439 | -357 | -136 | 79 | -326 | -7 | -19.85 | 63.9 | 115 | 149.4 | 71.7 |
| Net income 1 | 188 | 69 | -69 | -145 | 399 | -410 | -201 | 26 | -378 | -39 | -106 | -10 | 59 | 96 | - |
| Net margin | 8.91% | 3.14% | -3.6% | -7.37% | 19.5% | -18.7% | -10.34% | 1.2% | -16.89% | -1.62% | -4.93% | -0.43% | 2.45% | 3.86% | - |
| EPS 2 | 0.5200 | 0.1900 | -0.1900 | -0.4000 | 1.100 | -1.130 | -0.5500 | 0.0700 | -1.030 | -0.1100 | -0.1150 | 0.0650 | 0.1800 | 0.2550 | 0.1400 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 2/23/22 | 5/10/22 | 8/9/22 | 11/3/22 | 2/23/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/22/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 22,651 | 22,109 | 20,535 | - | - | 19,905 | 18,330 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 6.343 x | 6.712 x | 5.914 x | - | - | 6.12 x | 5.587 x | - |
| Free Cash Flow 1 | 1,231 | 809 | 1,157 | -946 | 817 | 1,521 | 1,576 | - |
| ROE (net income / shareholders' equity) | 82.1% | 179% | - | - | -665% | 300% | - | - |
| ROA (Net income/ Total Assets) | 4.7% | 4.39% | -3.14% | - | - | 1% | 1.5% | - |
| Assets 1 | -38,051 | -12,757 | 30,201 | - | - | 33,624 | 25,414 | - |
| Book Value Per Share 2 | 3.020 | 1.510 | - | - | - | -1.770 | -0.4000 | - |
| Cash Flow per Share 2 | 4.260 | 3.130 | 3.970 | -2.010 | 2.830 | 4.450 | 3.970 | - |
| Capex 1 | 270 | 302 | 269 | 218 | 215 | 254 | 217 | - |
| Capex / Sales | 3.14% | 3.76% | 3.19% | 2.68% | 2.46% | 2.71% | 2.29% | - |
| Announcement Date | 2/19/20 | 2/24/21 | 2/23/22 | 2/23/23 | 2/22/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
8.71
USD
Average target price
10.07
USD
Spread / Average Target
+15.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.60% | 3.19B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- BHC Stock
- Financials Bausch Health Companies Inc.
